Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
16
×
deals
16
×
life sciences
national blog main
biotech
boston top stories
boston
clinical trials
national top stories
san francisco blog main
san francisco top stories
fda
startups
new york blog main
new york top stories
sanofi
alnylam pharmaceuticals
investing
alexion pharmaceuticals
boehringer ingelheim
crispr
eli lilly
hepatitis b
ipo
rna interference
roche
vc
abbvie
akouos
allergan
amgen
autoimmune disorders
cancer
editas medicine
gene editing
genentech
glaxosmithkline
indiana blog main
indiana top stories
novartis
What
medicines
16
×
drug
deal
new
disease
research
bio
biotech
cancer
fda
gene
ipo
pharma
therapeutics
years
adds
ago
alliance
called
candidate
companies
company
date
developing
dicerna
diseases
editing
hepatitis
molecules
pact
pharmaceuticals
plans
potential
rna
roche
stakes
startup
synthetic
targets
team
Language
unset
Current search:
deals
×
medicines
×
" boston blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines